GRAFTON - Cedarburg
Hauser Pharmaceuticals has hired Alex Tretyakov as its director
of process development.
“In his 25-plus
years of industry experience, Alex has demonstrated a real
ability to streamline processes and drive growth via scientific
excellence,” said Tony Laughrey, CEO of Cedarburg Hauser
Pharmaceuticals. “We are counting on Dr. Tretyakov to help
accelerate Cedarburg Hauser’s growth and are excited to have him
lead Cedarburg Hauser’s process and analytical development
groups. He also will join John Lynch in serving as the technical
face of the company and infusing his insight into customer
has earned an excellent reputation in our industry by delivering
on-time solutions with quality chemistry,” said Chuck Boland,
executive vice president. “These attributes are important as
they ensure the success of a project and help establish
Cedarburg Hauser as an industry leader.”
Tretyakov served as vice president of research and development
at PCI Synthesis. He previously held the same position at
Cambridge Major Laboratories. He has a doctorate in organic
chemistry from the University of Oklahoma.
Hauser Pharmaceuticals is a contract development and
manufacturing organization specializing in small-molecule active
pharmaceutical ingredients and pharmaceutical intermediates.